| Chronic Ingestion of Flavan-3-ols and Isoflavones Improves Insulin Sensitivity and Lipoprotein Status and Attenuates Estimated 10-Year CVD Risk in Medicated Postmenopausal Women With Type 2 Diabetes: A 1-year, double-blind, randomized, controlled trial. | |
| | |
MedLine Citation:
|
PMID: 22250063 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVETo assess the effect of dietary flavonoids on cardiovascular disease (CVD) risk in postmenopausal women with type 2 diabetes on established statin and hypoglycemic therapy.RESEARCH DESIGN AND METHODSDespite being medicated, patients with type 2 diabetes have elevated CVD risk, particularly postmenopausal women. Although dietary flavonoids have been shown to reduce CVD risk factors in healthy participants, no long-term trials have examined the additional benefits of flavonoids to CVD risk in medicated postmenopausal women with type 2 diabetes. We conducted a parallel-design, placebo-controlled trial with type 2 diabetic patients randomized to consume 27 g/day (split dose) flavonoid-enriched chocolate (containing 850 mg flavan-3-ols [90 mg epicatechin] and 100 mg isoflavones [aglycone equivalents)]/day) or matched placebo for 1 year.RESULTSNinety-three patients completed the trial, and adherence was high (flavonoid 91.3%; placebo 91.6%). Compared with the placebo group, the combined flavonoid intervention resulted in a significant reduction in estimated peripheral insulin resistance (homeostasis model assessment of insulin resistance [HOMA-IR] -0.3 ± 0.2; P = 0.004) and improvement in insulin sensitivity (quantitative insulin sensitivity index [QUICKI] 0.003 ± 0.00; P = 0.04) as a result of a significant decrease in insulin levels (-0.8 ± 0.5 mU/L; P = 0.02). Significant reductions in total cholesterol:HDL-cholesterol (HDL-C) ratio (-0.2 ± 0.1; P = 0.01) and LDL-cholesterol (LDL-C) (-0.1 ± 0.1 mmol/L; P = 0.04) were also observed. Estimated 10-year total coronary heart disease risk (derived from UK Prospective Diabetes Study algorithm) was attenuated after flavonoid intervention (flavonoid +0.1 ± 0.3 vs. placebo 1.1 ± 0.3; P = 0.02). No effect on blood pressure, HbA(1c), or glucose was observed.CONCLUSIONSOne-year intervention with flavan-3-ols and isoflavones improved biomarkers of CVD risk, highlighting the additional benefit of flavonoids to standard drug therapy in managing CVD risk in postmenopausal type 2 diabetic patients. |
| | |
Authors:
|
Peter J Curtis; Mike Sampson; John Potter; Ketan Dhatariya; Paul A Kroon; Aedín Cassidy |
Related Documents
:
|
22205343 - Prevalence of the insulin receptor substrate-1(irs-1) gly972arg and the insulin recepto... 9739033 - Effects of soybean oil and fish oil emulsions on glucose and lipid metabolism in strept... 21483363 - Prevalence of obesity and its association with chronic kidney disease, hypertension and... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-16 |
Journal Detail:
|
Title: Diabetes care Volume: - ISSN: 1935-5548 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7805975 Medline TA: Diabetes Care Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich, Norfolk, U.K. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: On the Existence of A-Site Deficiency in Perovskites and Its Relation to the Electrochemical Perform...
Next Document: Retinal Vascular Geometry Predicts Incident Renal Dysfunction in Young People With Type 1 Diabetes.